BiOrion runs two active development programs. In the diagnostic imaging program BOT501 the bicyclic peptide is conjugated to a PET radionuclide. BOT501 is developed to identifying and stratifying patients with cardiac fibrosis, hepatic fibrosis or colorectal cancer as well as following up disease-specific targeted antifibrotic therapy.
In the therapeutic program BOT191 the bicyclic peptide is conjugated to the C-terminal signaling domain of interferon gamma. BOT191 is primarily developed for targeted antifibrotic therapy of patients suffering from cardiac fibrosis, hepatic fibrosis or colorectal cancer.